Hudson Bay Capital Management
APLS

Hudson Bay Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Hudson Bay Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$47.9M Buy
1,190,416
+10,588
+0.9% +$228K 0.17% 107
2025
Q4 		$29.6M Buy
1,179,828
+761,328
+182% +$17.9M 0.1% 180
2025
Q3 		$9.47M Sell
418,500
-56,500
-12% -$1.32M 0.03% 369
2025
Q2 		$8.22M Buy
475,000
+164,300
+53% +$3.04M 0.03% 408
2025
Q1 		$6.8M Sell
310,700
-34,300
-10% -$948K 0.02% 523
2024
Q4 		$11M Buy
345,000
+85,000
+33% +$2.56M 0.04% 346
2024
Q3 		$7.5M Buy
260,000
+145,000
+126% +$5.37M 0.03% 345
2024
Q2 		$4.41M Buy
115,000
+80,000
+229% +$3.62M 0.02% 401
2024
Q1 		$2.06M Buy
+35,000
New +$2.23M 0.01% 450
2023
Q4 		– Sell
-12,500
Closed -$476K – 716
2023
Q3 		$476K Buy
+12,500
New +$549K ﹤0.01% 603
2023
Q2 		– Sell
-50,000
Closed -$3.3M – 851
2023
Q1 		$3.3M Buy
+50,000
New +$2.89M 0.03% 407
2020
Q4 		– Sell
-60,000
Closed -$1.81M – 592
2020
Q3 		$1.81M Buy
+60,000
New +$1.79M 0.03% 373

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Hudson Bay Capital Management's APLS Position: Q1 2026 in Review

Hudson Bay Capital Management increased its Apellis Pharmaceuticals (APLS) stake by 0.9% in Q1 2026, buying an estimated $228K and bringing the position to 1,190,416 shares worth $47.9M. The position accounts for 0.17% of the portfolio, ranked #107.

Hudson Bay Capital Management first reported a position in APLS in Q3 2020 and has held it in 12 quarters since. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Hudson Bay Capital Management held 1,190,416 shares of Apellis Pharmaceuticals worth $47.9M as of Q1 2026.
  • Hudson Bay Capital Management bought 10,588 Apellis Pharmaceuticals shares in Q1 2026, an estimated $228K.
  • Apellis Pharmaceuticals made up 0.17% of Hudson Bay Capital Management's portfolio in Q1 2026, its #107 holding.
  • Hudson Bay Capital Management first reported a position in Apellis Pharmaceuticals in Q3 2020 and has held it in 12 quarters since.
  • 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.